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Abstract 
Background: Hepatocyte growth factor (HGF) is a cytokine that has a profound effect on cancer cells by stimulat‑
ing migration and invasion and acting as an angiogenic factor. In lung cancer, the factor also plays a pivotal role and 
is linked to a poor outcome in patients. In particular, HGF is known to work in combination with EGF on lung cancer 
cells. In the present study, we investigated the effect of a traditional Chinese medicine reported in cancer therapies, 
namely YangZheng XiaoJi (YZXJ) on lung cancer and on HGF mediated migration and invasion of lung cancer cells.
Methods: Human lung cancer cells, SKMES1 and A549 were used in the study. An extract from the medicine was 
used. Cell migration was investigated using the EVOS and by ECIS. Cell–matrix adhesion and in vitro invasion were 
assessed. In vivo growth of lung cancer was tested using an in vivo xenograft tumour model and activation of the 
HGF receptor in lung tumours by an immunofluorescence method.
Results: Both lung cancer cells increased their migration in response to HGF and responded to YZXJ by reducing 
their speed of migration. YZXJ markedly reduced the migration and in vitro invasiveness induced by HGF. It worked 
synergistically with PHA665752 and SU11274, HGF receptor inhibitors on the lung cancer cells both on HGF recep‑
tor activation and on cell functions. A combination of HGF and EGF resulted in a greater increase in cell migration, 
which was similarly inhibited by YZXJ, and in combination with the HGF receptor and EGF receptor inhibitors. In vivo, 
YZXJ reduced the rate of tumour growth and potentiated the effects of PHA665752 on tumour growth. It was further 
revealed that YZXJ significantly reduced the degree of phosphorylation of the HGF receptor in lung tumours.
Conclusion: YZXJ has a significant role in reducing the migration, invasion and in vivo tumour growth of lung cancer 
and acts to inhibit the migratory and invasive effects induced by HGF and indeed by HGF/EGF. This effect is likely 
attributed to the inhibition of the HGF receptor activation. These results indicate that YZXJ has a therapeutic role in 
lung cancer and that combined strategy with methods to block HGF and EGF should be considered.
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Background
Lung cancer is the leading cancer worldwide and results 
in more death than any other cancer types. In the UK, the 
incidence of lung cancer in males has steadily declined, 
but in contrast, the rate in females has steadily increased 
[1–3]. Worldwide, although the incidence rate has been 
declining in developed countries, since the later part of 
the last century, the incidence continues to rise in coun-
tries in which smoking has peaked including China, 
Korea, and several countries in Africa and will con-
tinue to do so for the next few decades [2, 4]. Treatment 
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options for lung cancer remain limited, which is reflected 
in the poor survival, namely 5  year survival remains 
below 10  % and 10  year survival close to 5  %. Surgery, 
chemotherapy and radiotherapy remain the main treat-
ment choice, although new targeted therapies are now 
available, namely anti-EGFR, etc. [3, 5, 6].
Recently, there have been early clinical reports that a 
Chinese medicinal formula, known as YangZheng XiaoJi 
(YZXJ), has a beneficial effect in patients with lung can-
cer [7, 8]. In a number of small trials, YangZheng XiaoJi, 
in combination with chemotherapy has been shown to 
increase the survival rate and at the same time, reduced 
the side effects. A similar beneficial effect has been 
reported in patients with primary hepatocellular car-
cinoma [9]. Although it was initially proposed that the 
beneficial effects may be due to the improved immune 
function, such as the increase in NK cell functions, there 
have been recent reports to show that YangZheng XiaoJi 
was able to directly inhibit angiogenesis and migration 
of cancer cells, including osteosarcoma cells, an effect 
attributable to the inhibition on the activation of focal 
adhesion kinase [10, 11].
Hepatocyte growth factor (HGF) is a cytokine that has 
strong effects on normal cells and cancer cells [12, 13]. 
In normal physiology, the cytokine is involved in tissue 
regeneration and organ repair, for example liver and lung 
regeneration. In cancer, however, the cytokine has been 
shown to have a profound effect on the migration, inva-
sion and growth of cancer cells and has acted as a pow-
erful angiogenic and lymphangiogenic factor [14, 15]. In 
the majority of solid tumour types, HGF and its receptor, 
cMET, have been found to be over-expressed in cancer 
cells and tumour tissues. It has been shown to be linked 
to disease progression, metastasis and long term clinical 
outcome of the patients [15–17].
In non-small cell lung cancer (NSCLC), HGF recep-
tor protein over-expression has been frequently dem-
onstrated [18, 19] and is shown to be associated with a 
poor clinical outcome of the patients. It has been shown 
that cMET protein expression is increased in NSCLC 
lung tumours with ALK gene rearrangement [20], and 
that gene amplification is uncommon in lung cancer. The 
amplified cMET protein expression may be the result of 
transcription factor ETS2 which was frequently down 
regulated in lung cancer [21].
In lung cancer, HGF has also been shown to inter-
fere with EGF tyrosine kinase activation, which in turn 
results in induced resistance to EGFR inhibitor therapies 
[22]. Thus, combined use of MET tyrosine kinase inhibi-
tor (TKI) and EGF TKI has been suggested to be a valid 
novel combination to overcome TGF TKI acquired resist-
ance in lung cancer [23]. This was indeed shown in an 
in vitro study in which the cMET small inhibitor E7050 
has the ability to circumvent resistance to the reversible, 
irreversible, and mutant-selective EGFR-TKIs induced 
by exogenous and/or endogenous HGF in EGFR mutant 
lung cancer cell lines, by blocking the Met/Gab1/PI3 K/
Akt pathway in  vitro [24]. It is interesting to note that 
HGF-positive serum is a predictive factor for patients 
negative response to gefitinib therapy with advanced 
NSCLC who harbour wild-type EGFR [25, 26]. Serum 
HGF levels have been shown to be linked to disease pro-
gression and overall survival, and interestingly even more 
so when EGFR status was considered [27].
cMET protein over-expression was seen in more than 
half of small cell lung cancer (SCLC) and patients with 
cMET phosphorylation in the SCLC tumours have a 
markedly poor overall survival (132 vs 287 days for those 
with cMET phosphorylated tumours and non-phospho-
rylated tumours respectively, p  <  0.001) [28]. Circulat-
ing HGF (cHGF) was found to be a regular feature for 
patients with lung cancer and has been suggested to be 
a useful biomarker in choosing a HGF/cMET based tar-
geted therapy [29, 30]. Lung cancer may attract neutro-
phils to release their HGF storage and contribute to the 
local microenvironment for lung cancer progression [31].
Previous reports have demonstrated a profound effect 
of YangZheng XiaoJi on the migration of cancer cells and 
indeed on endothelial cells, suggesting that the medicine 
is an important regulator for cell motility and potential 
target for therapy [32, 33]. HGF is one of the most pow-
erful motogens (motility stimulating cytokines) which, 
together with the HGF receptor, cMET, are aberrantly 
expressed in lung cancer. In the present study, we sought 
to investigate the effects of YangZheng XiaoJi on the 
migration, invasion and cell adhesion of lung cancer cells, 
in particular in the context of stimulation by HGF. In this 
context, the degree of the activation/phosphorylation of 
the HGF receptor was also investigated in order to deci-
pher if and how YangZheng XiaoJi might affect the HGF/
cMET complex. The study also examined the effect of 
YangZheng XiaoJi on the growth of lung tumours in vivo. 
Here, we report that YangZheng XiaoJi has an inhibitory 
effect on the functions and growth of lung cancer cells, 
in vitro and in vivo. YangZheng XiaoJi also exhibited an 
effect on HGF- and HGF/EGF-induced cellular migration 
on lung cancer cells and impacted on the phosphoryla-
tion of the HGF receptor, cMET.
Methods
Cells and materials
Human lung cancer cell lines, SKMES1 and A549 
were obtained from ATCC/LGC standard (Tedding-
ton, Middlesex, England, UK). Recombinant human 
hepatocyte growth factor was a kind gift from Profes-
sor Toshikazu Nakamura (Osaka University, Osaka, 
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Japan). Recombinant human EGF was from Sigma 
Aldrich (Poole, Dorset, England, UK). Small inhibitors 
to HGF receptor, SU11274 (IC50 for cMET 20  nM) and 
PHA665752 (IC50 for cMET 9  nM), and small inhibitor 
to the EGFR kinase, AG490 (IC50 for EGFR 2 µM) were 
obtained from Tocris Chemicals (Bristol, England, UK). 
Antibodies to human HGF, human cMET (SC-10), and 
phospho-cMET (sc-34088) were obtained from Santa 
Cruz Biotechnologies Inc., (Santa Cruz, CA, USA). Horse 
radish peroxidase (HRP) conjugated fluorescently tagged 
secondary antibodies were obtained from SigmaAldrich 
(Poole, Dorset, England, UK).
The herbal medicinal formula, YangZheng XiaoJi was 
obtained from Yiling Pharmaceuticals (Shijiazhuang, 
HeBei, China). The formula contained the following 16 
ingredients: Panax ginseng C.A. Mey., Astragalus meme-
branaceus (Fisch.) Bge.var. mongholicus (Bge.) Hsiao, 
Ligustrum lucidum Ait., Curcuma phaeocaulis Val., Gan-
odema lucidum, Gynostemma pentaphylla (Thunb) Mak, 
Atractylodes macrocephala Koidz, Scutellaria barbata 
D.Don, Oldenlandia diffusa (willd.) Roxb., Poria cocos, 
Duchesnea indica Focke, Solanum lyratum Thunb., Arte-
misia scoparia (Bge.) Ki, Cynanchum paniculatum Kitag, 
Eupolyphaga sinensis Walker, and Gallus domesticus 
Brisson. The chemical fingerprints of different batches 
were found to be highly consistent. Shown in Additional 
file  1 are fingerprints from 10 batches of YangZheng 
XiaoJi over a 2 year period (Additional file 1).
YangZheng XiaoJi extract, referred to as DME25, was 
prepared from YangZheng XiaoJi as previously reported 
using a DMSO based method [8, 10, 34]. Briefly, YangZ-
heng XiaoJi formulated powder was added to pure DMSO 
solution (Sigma Aldrich). This was placed on a rotat-
ing wheel (Labinco BV, Wolf Laboratory, York, England, 
UK) for 12  h in a cold room at 4  °C at 100  rpm [8, 10]. 
The preparation was centrifuged at 15,000×g, for 20 min 
at 4  °C. The supernatant was carefully removed and fil-
tered using a disc filtration unit (pore size 0.20 μm, Sar-
torius Stedim, Sartorius, Epson, Surrey, England, UK). 
The extract was diluted in a balanced salt solution (BSS) 
and standardised by quantifying the optical density of the 
preparation using a spectrophotometer at 450 nm wave-
length (Biotek, Wolf Laboratory). A master preparation 
which gave 0.25 OD at 450 nm was stored as the master 
stock and so named as DME25 for the subsequent experi-
ments. DME25 at dilutions below 1:40 did not show an 
effect on the growth of lung cancer cells. In the present 
study, we used the dilution range between 1:100 to 1:2000.
Electric cell‑substrate impedance sensing (ECIS) based cell 
adhesion and cell migration assays
This was modified from a method previously described 
[35, 36]. Briefly, 96-well W96E1 microarrays were used 
on the ECIS Ztheta instrument (Applied Biophysics Ltd, 
Troy, New Jersey, USA). Lung cancer cells were added 
to the wells of the array, followed by immediate track-
ing of cell adhesion over a range of frequencies, namely 
from 1000 to 64,000  Hz using automated modules. The 
adhesion was analysed using the mathematical modelling 
methods as previous described [37]. For cellular migra-
tion, confluent lung cancer monolayers in the arrays were 
electrically wounded (2000 mA for 20 s each), after which 
the migration of the cells was immediately tracked, again 
over a range of frequencies. All the experiments were 
conducted in triplicate.
EVOS cellular migration assay (wounding assay)
Cellular migration assays were conducted on an EVOS 
system (EVOStm fl Digital Inverted Fluorescence Micro-
scope, Fisher Scientific, Paisley, Scotland, UK). The 
human-interface free system integrated automated digi-
tal time lapse recording, temperature and air control, 
automated sampling of same sample point over a speci-
fied time and over large number of replicates (up to 96 
wells).
Cells were seeded into a 96-well plate (Nunc, Fisher 
Scientific, Paisley, Scotland, UK) at 10,000 per well and 
allowed to reach full confluence overnight in the incu-
bator. The monolayer was then scratched using a fine 
tipped plastic pipette to create a wound of approximately 
200 µm wide. The media together with the floating cells 
were removed and replaced with media containing eith-
erYangZheng XiaoJi extract alone (1:1000), or in combi-
nation with HGF (50  ng/ml) or HGF receptor inhibitor 
(PHA665752 10  nM, SU11274 20  nM, based on their 
IC50 value). Each treatment was done in quadruplicate 
wells. The plate was immediately placed in the chamber 
of the EVOS unit (which was programmed to supply 5 % 
CO2 and maintained at 37 °C constant temperature). The 
EVOS was programmed to memorise the three dimen-
sional position of the wounding position in each well and 
then automatically tracked the image of each well, every 
15  min for up to 9  h. Sequential images were analysed 
using Image J software. Four images were randomly cho-
sen, one from a replicate at the beginning of the experi-
ment and at the end of each hour. Due to the nature of 
the wound front (leading front of the wounded cell mon-
olayer), 10 points were chosen randomly in each image 
and the distance between the opposing fronts at each 
point was then measured. Together, distance at 40 points 
for each treatment was quantified. The net distance that 
the cell migrated at each point was calculated as: dis-
tance migrated = (T0 − Tn)/2, where T0 is the distance 
between two leading wound edges at the beginning of the 
experiment, and Tn is the distance between the wound 
leading edge of the same wounding point at a given time 
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and at a given point (38). The distance is shown as the 
mean number of pixels that cells had migrated from the 
4 replicates. The migration is shown as a time course, and 
the comparison between the experimental settings was 
based on a fix time point.
In vitro invasion assay
Invasion assays were performed based on a previously 
published method [38]. Transwell invasion inserts with 
pore size at 8.0 µm were first coated with 50 µg Matrigel 
and allowed to air dry. The gel was then carefully rehy-
drated. To each insert, 30,000 cancer cells were added 
together with the test agents or their combinations. After 
72  h, Matrigel and non-invading cells were removed 
using a cotton swab. Invaded cells on the lower surface 
of the inserts were fixed with 4 % formaldehyde and then 
stained with 1  % crystal violet. The number of invaded 
cells were counted under a microscope.
SDS PAGE and western blot
Lung cancer cells at sub-confluence were first sub-
jected to serum hunger for 4  h in a serum free culture 
medium. The test agents including HGF (50  ng/ml), 
DME25 (1:1000), PHA665752 (10  nM), or their combi-
nations were respectively added to the cells for a period 
of 45 min. Sodium orthovanadate (100 µM) with hydro-
gen peroxide (0.1 %) was used as a positive control. Cells 
were collected using a cell scrapper. After centrifugation 
(1000  rpm for 5  min), media were removed from the 
cell pellets. Proteins from the cell pellets were extracted 
using a lysis buffer that contained 1.5 % Triton X100 as 
detergent, and protease inhibitors. Protein concentra-
tions were standardised. Equal amount of proteins were 
loaded onto 8  % SDS PAGE. After separation, proteins 
were blotted onto nitrocellulose membrane, which were 
subsequently probed by specific antibodies to total 
MET, phospho-MET (p-MET) and GAPDH. The pro-
tein blocking solution contained 1 % horse serum. After 
probing with horse-radish peroxidase conjugated anti-
bodies, the protein signal was detected using chemilu-
minescence methods (EZ ECL, Cellseco Ltd., Salisbury, 
Wiltshire, England, UK) and images were taken on a 
luminescent/fluorescent imager (Syngene, G: Box, Cam-
bridge, England). The protein band signal was quantified 
using Image-J software. Shown here as pMET/cMET 
ratio.
In vivo tumour model
Athymic female nude mice, CD-1 of 4–6  weeks old 
were purchased from Charles River Laboratories (Mar-
gate, Kent, England, UK). Due to the sensitive response 
to DME25 and the HGF receptor inhibitors, we chose 
A549 cell line for the in  vivo tumour model. Tumour 
cells, which were prepared at 5  ×  106/ml in a solution 
containing 3  mg/ml Matrigel, was injected subcutane-
ously to give 0.5 million cells per injection [39, 40]. After 
one week when tumours became visible, mice were ran-
domly divided into groups (n  =  6 in each group). The 
size of tumours were measured using digital callipers. 
Treatments began one week after tumour cell inocula-
tion and included the following: Control group (receiving 
control buffer), YangZheng XiaoJi extract via intraperi-
toneal injection (IP) or by gavage (oral), cMET inhibi-
tor (PHA665752), a combination of YangZheng XiaoJi 
extract and cMET inhibitor. Treatments were given daily. 
The final concentration of YangZheng XiaoJi extract was 
1  µl/g body weight and PHA665752 6.4  ng/gram body 
weight. Tumour size was measured weekly for 4  weeks. 
Mice were weighed and monitored daily. The procedure 
was reviewed and approved by the Cardiff University 
Joint Biological Ethics Committee and conducted under 
the UK Home Office Project License (PPL 30/2591). At 
the conclusion of the experiments, mice were terminated 
by euthanasia. Tumours were dissected and immediately 
stored at −80  °C for subsequent analysis. Tumour vol-
umes were calculated by the following formula: tumour 
volume (mm3) = length × width × 0.54 [41].
Immunofluorescence staining
Frozen tumours were sectioned using a cryostat (Leica 
CM1900) at 7 µm thickness. After fixation using acetone/
methanol fixation buffer, the slides were rehydrated and 
blocked with a Tris buffer (25  mM, pH 8.4) that con-
tained 10  % horse serum for 1  h. Primary antibodies 
(including anti-cMET, anti-pMET), diluted in the block-
ing buffer was added to the respective slides which were 
kept in a humidified box for 1  h, and then thoroughly 
washed. FITC- or TRITC tagged secondary antibodies 
were then added to the respective slides together with 
DAPI for nuclear counter stain. After 1 h, the slides were 
thoroughly washed and mounted using FluroSave™ (Cal-
biochem, Nottingham, England, UK). The slides were 
examined on an Olympus microscope and photographed 
using a Hamamatsu digital camera. The staining intensity 
was determined using Image-J. Briefly, the images were 
first converted to greyscale andthe staining intensity at 
the cell–cell junction areas where cMET is located, were 
calculated from Image-J, minus the reading from a back-
ground control. Eight images were calculated from each 
staining.
Statistical analysis
Statistical analysis was carried out using Sigma Plot 
(version 11, Systat Software Inc., San Jose, CA, USA). 
ANOVA test was used on normalised data and ranked 
ANOVA was used on non-normalised data.
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Results
YangZheng XiaoJi had a profound influence on cell–matrix 
adhesion, cell migration and in vitro invasion
The effect of YangZheng XiaoJi was firstly tested on cel-
lular migration. Using automatic cell tracking with the 
EVOS system, it was shown that YangZheng XiaoJi sig-
nificantly reduced the migration speed of lung cancer 
cells (Fig. 1a, b). As expected, HGF increased the speed of 
migration of both cancer cells. It is interesting to observe 
that inclusion of YangZheng XiaoJi significantly reduced 
the pace of migration (Fig. 1c, d). Likewise, in vitro inva-
siveness was also tested. As shown in Fig.  1e, f, YangZ-
heng XiaoJi also significantly reduced invasiveness of 
both cells.
In the study, we also employed another automated 
method in tracking cell adhesion and migration, 
namely an ECIS based method. As shown in Fig. 2a, b, 
YangZheng XiaoJi had some marked inhibitory effects 
on the adhesion of both cells. An electric wounding 
based method was applied to confluent lung cancer 
cells followed by tracking the migration of both cells. 
As shown in Fig.  2c, the migration of SKMES1 cells 
was markedly suppressed by YangZheng XiaoJi. A549 
cells exhibited a similar response to YangZheng XiaoJi, 
in that repeated wounding demonstrated a similar 
response (Fig. 2d).
YangZheng XiaoJi had a synergistic effect with cMET 
kinase inhibitors on HGF induced effects on lung cancer 
cells
To evaluate the potential interplay between YangZ-
heng XiaoJi and HGF/cMET, the effects of combining 
YangZheng XiaoJi and cMET kinase inhibitors, namely 
PHA665752 and SU11274, was tested. Using the EVOS 
method, it was found that YangZheng XiaoJi potenti-
ated the effects of both inhibitors on cellular migration 
of both cells (Fig.  3A–D). Likewise, YangZheng XiaoJi 
also increased the inhibitory effect of both inhibitors on 
in  vitro invasiveness of both cells (Fig.  3A–D). Overall, 
A549 seems to be more sensitive than SKMES1 in the 
response to HGF, the cMET inhibitors and to DME25.
A similar observation was made when using the ECIS 
method in tracking cell adhesion (Fig.  4a–d) and cell 
migration (Fig.  4e–h) for both SKMES1 (a, b, e, f ) and 
A549 (c, d, g, h). Figure 4 also demonstrates, in 3D imag-
ing, the cell migration over a range of frequencies.
YangZheng XiaoJi had an inhibitory effect on the 
phosphorylation of the HGF receptor, cMET
The effect of YangZheng XiaoJi extract was further evalu-
ated, directly or in combination with cMET small inhibi-
tor PHA665752, on the action of the HGF receptor. In 
quiescent cells (4  h after serum hunger, only traceable 
Fig. 1 Effects of YangZheng XiaoJi on cell migration, adhesion and invasion. a Cell images from A549 wounding model. Left control group in which 
cell monolayer was wounding and monitored continuously for 8 h. Right DME25 treated group, similarly wounded and monitored. DME25 dilution 
used was 1:1000. b Cellular migration of A549 as tracked by EVOS imaging system and quantified migration speed (in pixels). YangZheng XiaoJi had 
a significant inhibitory effect on the migration (p < 0.001). c, d YangZheng XiaoJi HGF‑induced cell migration (shown are at 6 h after wounding). HGF 
(shown at 50 ng/ml) had a significant stimulatory effects on cell migration of both A549 (d) (p < 0.05 vs control) and to some degree SKMES1 cells 
(c) (p = 0.08). YangZheng XiaoJi inhibited HGF‑induced cell migration (p < 0.05 vs control, p < 0.05 vs with HGF only). e, f Effects of YangZheng XiaoJi 
on cell invasion. YangZheng XiaoJi inhibited in vitro invasion of both cells (p < 0.05 vs control)
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amounts of pMET was detected in control cells (Fig.  5, 
top), which was significantly inhibited by DME25, 
PHA665752 and their combination (Fig. 5, top) (p < 0.01 
vs control, Fig.  5, bottom). HGF resulted in a marked 
activation of the receptor (p < 0.01 vs without HGF con-
trol) (Fig.  5, bottom). Neither PHA665752 nor DME25 
alone exhibited significant inhibition on the HGF acti-
vation of its receptor (p  >  0.05). However, it was very 
interesting to note that the combination of PHA665752 
and DME25 resulted in a significant inhibition in HGF-
induced receptor phosphorylation (Fig. 5).
Anti‑tumour effects exerted by YangZheng XiaoJi in vivo
Using an in vivo A549 tumour model, it was shown that 
YangZheng XiaoJi, delivered daily, had a significant inhib-
itory effect on tumour growth (Fig.  6). The peritoneal 
route appeared to be more effective than the oral route 
(Fig.  6a). The cMET kinase inhibitor, PHA665752 also 
had an effect on slowing down the growth, in a similar 
manner as YangZheng XiaoJi (Fig. 6b). A combination of 
YangZheng XiaoJi and PHA665752 showed a more pro-
found inhibitory effect on the growth of A549 tumours 
(Fig. 6b, the oral route of delivery of all the agents after 
3 weeks treatment).
Immunofluorescence staining for HGF receptor and 
the receptor activation further demonstrated the effect of 
the treatment on the HGF receptor. As shown in Fig. 7a, 
left and b1, the three treatments resulted in some degree 
of reduction of the staining of total MET. However, when 
the activated receptor was examined, results revealed 
both YangZheng XiaoJi and PHA665752, and in particu-
lar their combination, markedly reduced the intensity of 
Fig. 2 Electric cell‑substrate impedance sensing (ECIS) based evaluation of cell adhesion (a, b) and cellular migration (c, d). a, b Evaluation of cell 
adhesion by ECIS. The ECIS array was first treated with cysteine for 20 min followed by washing. Medium or tested agents were then pipetted to 
the respective wells, immediately followed by adding cancer cells to each well. The ECIS unit then immediately began tracking the adhesion of the 
cells. Shown are traces of the adhesion of the respective cells. Cell adhesion of SKMES1 and A549 to matrix was markedly inhibited by YangZheng 
XiaoJi (shown is the extract used at 1:1000). Error bars shown are standard deviation (n = 4). YangZheng XiaoJi significantly inhibited the adhesion 
of both cells (p < 0.05, control vs DME25 treatment). c Effects of YangZheng XiaoJi on the migration of SKMES1 cells analysed by ECIS. SKMES1 cells, 
after reaching confluence, were electrically wounded (indicated by arrow). After replacing the medium with fresh medium contained test agent, 
the pace of migration was immediately traced. Shown are the cell response in a 3‑D model: resistance in y‑axis (ohms), over a 7‑h period (z‑axis) and 
across 7 frequencies (1000, 2000, 4000, 8000, 16,000, 32,000 and 64,000 Hz) (x‑axis). Observations were made with multiple frequencies in order to 
track if cell behaviour can be viewed differently over a broad spectrum of frequencies. The cellular migration of SKMES1 after electric wounding was 
suppressed by YangZheng XiaoJi (c2), compared with control (c1). d Effects of YangZheng XiaoJi on the migration of A549 cells analysed by ECIS. 
Test condition was the same as SKMES1 in (c), except that 7 h after the first round of wounding, a second wounding assay was applied, in order to 
evaluate the reproducibility of the same cell in the same model (indicated by the 2nd arrow in d1, d2). Similarly, the migration of A549 (d) was also 
inhibited by YangZheng XiaoJi. The A549 cells were repeatedly wounded and a similar inhibition was seen (d). c, d y-axis: resistance (ohms); x-axis: 
frequencies in Hz; z-axis: time in hours
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the activation of MET (phospho-MET) (Fig. 7a, right and 
b2).
YangZheng XiaoJi and the interplay between HGF 
and EGFR‑TK complexes
In order to evaluate the possible interplay between Yang-
Zheng XiaoJi and the HGF/EGF axis, we further evalu-
ated the effect of the medicine on HGF and HGF/EGF 
induced cell migration and cell growth. In cell migra-
tion assays, as shown in Fig. 8, the HGF/EGF combina-
tion markedly induced an increase in the migration of 
A549 cells (Fig. 8a, b) and particularly in that of SKMES1 
cells (Fig.  8c). As demonstrated earlier, YZXJ was able 
to significantly inhibit the migration of both cells, both 
HGF/EGF treated and untreated cells. Inhibitor to the 
HGF receptor (PHA665752) at the concentrations used, 
showed a significant inhibitory effect on HGF/EGF 
induced cell migration. The effect of EGFR inhibitor 
(AG490) was somewhat less effective. The combination 
of PHA665752 with YZXJ and to a certain degree AG490 
had a stronger effect. However, the strongest effects 
were seen when PHA665752, AG490 and YZXJ were 
Fig. 3 The effect of YangZheng XiaoJi and cMET kinase inhibitors, PHA665752 and SU11274 on HGF‑induced cell migration (A, B, C, D) and inva‑
sion (a, b, c, d), on both SKMES1 (top panel) and A549 (bottom panel) cells. Migration assay A both PHA665752 (10 nM) and SU11274 (20 nM) had 
a significant effect on HGF‑induced migration of SKMES1 cells. HGF concentration shown here is 50 ng/ml. *p < 0.01 cells with HGF/PHA665752 
combination vs cells with control medium only; **p < 0.05 cells with HGF/SU11274 combination vs cells with HGF only. Ɵp = 0.059 cells with HGF 
alone vs cells with control medium. B The effect of the combination between DME25 and HGF inhibitors on SKMES1 cells. *p < 0.05 cells with HGF/
SU11274 (or HGF/PHA665752) combination vs cells with HGF only; **p < 0.05 cells with HGF/SU11274/DME25 (or HGF/PHA665752/DME25) combi‑
nation vs cells with HGF only; #p < 0.05 cells with HGF/PHA665752 combination vs cells with control medium only; Ɵp = 0.059 cells with HGF alone 
vs cells with control medium. C effect of HGF and HGF receptor inhibitors on the migration of A549 cells. *p < 0.01 cells with HGF/SU11274 (or HGF/
PHA665752) combination vs cells with HGF only; #p < 0.05 respective cells vs cells with control medium only. D effect of HGF, and the combina‑
tion of DME25 and HGF receptor inhibitors on the migration of A549 cells. *p < 0.01 cells with HGF/SU11274 (or HGF/PHA665752) combination vs 
cells with HGF only; **p < 0.05 cells with HGF/SU11274/DME25 (or HGF/PHA665752/DME25, or HGF/DME25) combination vs cells with HGF only; 
#p < 0.05 respective cells vs cells with control medium only. Invasion assay a, b DME25 significantly potentiated the effect of HGF receptor inhibi‑
tors, PHA665752 (a) and SU121274 (b), on HGF‑induced invasion of SKMES1 cells. The effects were almost identical on both compounds. *p < 0.01 
treatment plus DME25 vs respective treatment without DME25 control; **p < 0.05 treatment plus DME25 vs respective treatment without DME25 
control; #p < 0.05 respective cells vs cells with control medium only. c, d Effects of DME25 on HGF and HGF receptor inhibitors, PHA665752 (c) and 
SU121274 (d), on HGF‑induced invasion of A549 cells. *p < 0.01 treatment plus DME25 vs respective treatment without DME25 control; **p < 0.05 
treatment plus DME25 vs respective treatment without DME25 control; # p < 0.05 respective cells vs cells with control medium only. The concentra‑
tions use for the test agents were: PHA665752—10 nM, SU11274—20 nM, HGF—50 ng/ml and DME25—1:1000 dilution
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combined, and this effect was particularly strong in HGF/
EGF induced migration in SKMES1 cells.
Discussion
In the present study, we have described for the first time that 
a traditional Chinese medicine formula, YangZheng XiaoJi 
has a profound direct effect on HGF induced aggressiveness 
of human lung cancer cells, both in vitro and in vivo. Fur-
thermore, the medicine is also shown to inhibit the migra-
tory effect induced by a combination of HGF and EGF, an 
axis of evil in clinical lung cancer in which they work syner-
gistically in stimulating the progression of lung cancers.
HGF, and indeed its receptor cMET, are a pair of 
proteins that have been found to be frequently over-
expressed in clinical lung cancers. In patients, raised lev-
els of circulating HGF are frequently seen and, together 
with over-expression of HGF receptor, it is an evil pair of 
proteins causing the progression of lung cancer [8–21, 
42]. HGF has some well established effects on cancer 
cells, including lung cancer cells. First, it is a power-
ful cellular migration and cellular invasiveness inducing 
factor, which earned it’s other name ‘scatter factor’; sec-
ond, HGF is a potent angiogenic and lymphangiogenic 
factor; third, it acts as a mitogen for cells, although this 
Fig. 4 ECIS based tracking cell adhesion (a, b, c, d) and cell migration (e, f, g, h) for both SKMES1 (a, b, e, f) and A549 (c, d, g, h). i, j 3D modelling 
was used to display the response of cell migration over frequencies ranging from 1000 to 64,000 Hz. The experimental conditions for both adhesion 
and migration are similar to that in Fig. 2. a, b Adhesion of SKMES1 cells. HGF increased the migration, which was blocked by inclusion of DME25 
and in particular by the combination of both DME25 and PHA665752 (a) and SU11274 (b). c, d: Adhesion of A549 cells. HGF had a marked effect on 
the adhesion of the cells, which was similarly reduced by DME25 and the cMET small inhibitors PHA665752 (c) and SU11274 (d). e, f Migration of 
SKMES1 cells following electric wounding. DME25, PHA665752 (e) and SU11274 (f) had a marked inhibitory effect on HGF induced cell migration. 
g, h Migration of A549 in a similar layout to (e, f), except the cell layer was wounded twice (at the beginning and after 8 h. i Adhesion of SKMES1 
cells as demonstrated using a 3‑dimensional model. The test was automatically carried out over a range of frequencies (1000 to 64,000 Hz). The 
inhibitory effect was seen across the range of frequencies applied in the study. J Migration of A549 cells shown in 3‑D model. The A549 cells were 
wounded at the beginning and after 8 h. Wounding condition was 2wounded. y-axis: resistance (ohms); x-axis: frequencies in Hz; z-axis: time in 
hours. The concentrations of the test agents used here were the same as in Fig. 3
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is mainly seen in normal hepatocytes. There has been 
compelling evidence to show that they are very credible 
targets in cancer treatment. Indeed, the past few years 
has witnessed the development of therapeutic methods, 
namely small molecules and neutralising antibodies, to 
target HGF and its receptor, with some now being used 
in patients. HGF receptor inhibitors have been shown 
to reverse HGF induced EMT in lung cancer cells [19]. 
cMET over-expression has been shown to respond to 
cMET monoclonal (MAB) treatment as second line ther-
apies by increasing overall survival and progression free 
survival [43]. In a recent study, PHA665752 has similarly 
been shown to block HGF induced effects on lung can-
cer cells [28]. Blocking HGF/cMET pathways by way of 
Fig. 5 YangZheng XiaoJi had an inhibitory effect on the activation of the HGF receptor, cMET in lung cancer cell, A549. Top images from immu‑
noblot assay. The phospho‑MET (pMET), total MET (cMET) and the loading control GAPDH were probed with the respective antibodies. Bottom 
the pMET/cMET band density ratio for the immunoblots. The medicinal extract, DME25 was used at 1:1000 and cMET small inhibitor PHA665752 
at 10 nM. Positive control for protein tyrosine phosphorylation was sodium orthovanadate (100 µM) with hydrogen peroxide (0.1 %). In quiescent 
cells, the limited activation of pMET was marked reduced by DME25, PHA665752 and the combination as indicated by asterisk. HGF caused marked 
action of the receptor (p < 0.01). The HGF induced activation was significantly inhibited by the DME25/PHA665752 combination (asterisk), however 
only marginally by DME25 alone (ap = 0.13 vs with HGF only) and PHA665752 (bp = 0.14, vs with HGF only)
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small kinase inhibitors, neutralising antibodies [44] and 
antagonist [45] have been shown to be viable new treat-
ments for lung cancer.
The current study has shown that the Chinese medi-
cine, YangZheng XiaoJi, has a strong inhibitory effect 
on HGF induced cellular migration of the lung cancer 
cells tested. The study has further demonstrated that 
YangZheng XiaoJi is able to work with the cMET inhib-
itor in a synergistic manner in extending the inhibi-
tory effects on the migration of cancer cells. The effect 
appears to be replicated in the in vivo models, in which 
the combination of YangZheng XiaoJi and PHA665752, 
the cMET inhibitor, can markedly increase the inhibi-
tory effects seen by individual agents alone. Thus, the 
study has presented a coherent observation that Yang-
Zheng XiaoJi, a traditional medicine currently being 
used in certain patients with cancer for example liver 
cancer, also has a therapeutic value in non-small cell 
lung cancer. In fact, in some small non-random stud-
ies, some benefits to the patients with lung cancer have 
already been reported although with little mechanistic 
studies.
The effects of YangZheng XiaoJi on the in vivo growth 
of lung cancer are more likely to be via multiple actions. 
The present study has reported a direct effect of the med-
icine on lung cancer cells. We have previously reported 
that the medicine also has a direct effect on angiogenesis 
in vitro and in vivo [10, 11]. Thus, it is plausible that the 
anti-tumour effects, in vivo, are via the direct action on 
cancer and on the microenvironment, namely angiogen-
esis. However, there have also been reports to show that 
patients who received the medicine have an improved 
immune function, for example favourable changes in NK 
cells and circulating cytokines. Thus, the anti-tumour 
and the therapeutic effect of the medicine are likely to be 
due to multiple factors.
The study has shown that application of YangZheng 
XiaoJi in tumour models has a significant effect on the 
levels of cMET, and most markedly activated cMET. In 
fact, both YangZheng XiaoJi and PHA665752 caused a 
reduction of cMET and phospho-cMET. The combi-
nation of both agents almost completely blocked the 
appearance of phospho-cMET in lung tumours. These 
observations suggest that blocking the HGF recep-
tor activation is a key mechanism by which YangZheng 
XiaoJi has its biological influence on lung cancer cells. It 
has been previously reported that YangZheng XiaoJi also 
impacts on the focal adhesion kinase (FAK), the AKT and 
sonic hedgehog (SHH) pathways in cancer cells and vas-
cular endothelial cells. The broad effect on multiple sig-
nalling pathways by YangZheng XiaoJi is not surprising, 
given that the medicine is a formula made of 16 herbal 
medicines. It is argued therefore that the medicinal for-
mula of a mixture of ingredients would work on multiple 
targets. Future work to explore the nature of the ingredi-
ents would be highly desirable.
Fig. 6 Effects of YangZheng XiaoJi and the cMET kinase inhibitor PHA665752 on the growth of A549 tumours. a Comparison between intraperito‑
neal and oral delivery of YangZheng XiaoJi on tumour growth, 3 weeks after treatments. IP route appears to be more effective than the oral route. 
*p < 0.01, **p = 0.05 vs control. b The effects of YangZheng XiaoJi, PHA665752 and their combination on the growth. All the treatments were via 
the oral route. The final concentration for YangZheng XiaoJi extract was 1 µl/g body weight and PHA665752 6.4 ng/g body weight. Tumour volume 
shown are mean ± SD in cubic milimeter
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EGF receptor kinase inhibitors are now widely used in 
the treatment of lung cancer [7]. However, recent reports 
to show that HGF can trans-activate EGFR and make the 
anti-EGFR therapy less effective or indeed make lung 
cancer resistant to EGFR therapy in lung cancer [22–24] 
are very interesting indeed. Methods in targeting both 
have been suggested to be a viable option in enhancing 
the effect of anti-EGFR based therapies [46, 47]. Our 
study has shown that HGF and EGF had a profound 
effect on the migration of lung cancer cells. It is interest-
ing to also note that AG490, an EGFR inhibitor has only 
marginal influence on this effect induced by HGF and 
EGF. We have shown that both YangZheng XiaoJi and 
PHA665752 are able to reduce the stimulation, and that 
a combination of the medicine, PHA665752 and AG490 
almost completely abolished the effect of HGF/EGF. 
This indicates that combined use of YangZheng XiaoJi 
and HGF receptor inhibitor is an effective way to over-
come resistance to anti-EGFR therapy in lung cancer and 
should be explored in clinical settings. Furthermore, it 
suggests that monitoring both HGF and EGF receptors 
are highly plausible in devising therapies for the patients.
Conclusion
The present study has shown that YangZheng XiaoJi has 
some significant effects on the migration and invasion of 
lung cancer cells and in vivo tumour growth. The effect 
is particularly profound on the functions induced by 
HGF and the HGF/EGF combination and is attributable 
to the inhibition of HGF receptor activation. The medi-
cine is particularly effective when used together with the 
HGF receptor inhibitors. It is concluded that YangZheng 
Fig. 7 Immunofluorescence staining of total MET and phospho‑MET (pMET 1384) in lung tumours from the in vivo model. a Immunofluorescence 
images of total MET (left panel) and phospho‑MET (pMET 1384) (right panel) in lung tumours. Images were taken using an objective lens at ×40. 
Scale bars represent 50 µm. b quantified staining in the intercellular areas. b1 total MET; b2 phospho‑MET (pMET). *p < 0.05 vs control; ** vs YZXJ 
alone and PHA665752 alone
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XiaoJi has a strong effect on HGF-induced cell adhesion 
and migration, which may be important when consider-
ing devising therapies in lung cancer and in the context 
of using the HGF/EGF receptor inhibitors in lung cancer.
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